## 2-(2-furanyl)-3-(6-methyl-2-pyridinyl)-4-quinazolinone: A promising anti-cancer agent
**2-(2-furanyl)-3-(6-methyl-2-pyridinyl)-4-quinazolinone**, also known as **FMPQ**, is a synthetic compound with a complex chemical structure containing a quinazolinone core, a furan ring, and a pyridinyl ring.
**Why is FMPQ important for research?**
FMPQ has demonstrated significant potential as an **anti-cancer agent** due to its unique pharmacological properties:
* **CDK Inhibition:** FMPQ is a potent inhibitor of cyclin-dependent kinases (CDKs), which are key enzymes involved in cell cycle regulation. By inhibiting CDKs, FMPQ can block cell proliferation and induce apoptosis (programmed cell death) in cancer cells.
* **Anti-angiogenic Activity:** FMPQ has been shown to inhibit angiogenesis, the formation of new blood vessels that supply tumors with nutrients and oxygen. This property further enhances its potential for cancer treatment.
* **Low Toxicity:** Studies have shown that FMPQ exhibits a favorable safety profile with minimal side effects, suggesting its potential for clinical application.
**Current Research and Future Prospects:**
* **Preclinical Studies:** Extensive preclinical studies have been conducted on FMPQ, demonstrating its efficacy against various cancer types, including leukemia, breast cancer, and lung cancer.
* **Clinical Trials:** FMPQ is currently undergoing clinical trials to assess its safety and effectiveness in humans. These trials are evaluating its potential for treating different types of cancer, and the results are eagerly awaited.
**Overall, 2-(2-furanyl)-3-(6-methyl-2-pyridinyl)-4-quinazolinone holds promise as a novel anti-cancer agent. Its potent CDK inhibitory activity, anti-angiogenic properties, and favorable safety profile make it a valuable candidate for further investigation and development.**
It's important to note that research on FMPQ is still ongoing, and its clinical application remains to be fully established. However, the promising results obtained so far provide hope for its potential contribution to cancer therapy in the future.
ID Source | ID |
---|---|
PubMed CID | 827877 |
CHEMBL ID | 1376592 |
CHEBI ID | 105298 |
Synonym |
---|
2-(furan-2-yl)-3-(6-methylpyridin-2-yl)quinazolin-4-one |
OPREA1_768386 |
OPREA1_044690 |
STK091230 |
2-(furan-2-yl)-3-(6-methylpyridin-2-yl)quinazolin-4(3h)-one |
smr000105691 |
MLS000109752 |
CHEBI:105298 |
AKOS000661190 |
HMS2301I15 |
CHEMBL1376592 |
2-(2-furanyl)-3-(6-methyl-2-pyridinyl)-4-quinazolinone |
Q27183014 |
2-(2-furyl)-3-(6-methyl-2-pyridyl)-4(3h)-quinazolinone |
way-300173 |
Class | Description |
---|---|
quinazolines | Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 112.2020 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |